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Abstract Nebulization for the administration of high doses of inhaled corticosteroids can benefit steroid-dependent 
asthmatics. The objective of this double-blind, double-dummy, multicentre, randomized, parallel-group study was to 
compare the efficacy and safety of high-dose cotiicosteroids given by nebulization or metered-dose inhalation in adult 
patients with asthma. Following a 2-weelk run-in period, I24 patients, aged I 8-70 years, with moderate to severe asthma 
treated with high-dose inhaled steroids were randomized to one of two treatment groups for I2 weeks: beclometasone 
dipropionate (BDP) suspension for nebulization 3000JtOOO~gday-1 b.i.d. given via a nebulizer (n=63), or BDP spray 
l500-2000pgda)rl b.i.d. given via a metered-dose inhaler (MU) plus spacer (BDP MDI) (n=6l). Comparable 
improvements over baseline, which were statistically signiticant in most cases, were reported at study end for the two 
treatment groups in the various efficacy parameters evaluated (pulmonary function tests, clinical symptoms scores, and the 
use of rescue salbutamol).The primary efficacy endpoint was morning pulmonary expiratory flow rate (PEFR). For the 
intent-to-treat population, in the BDP nebulization group mean morning PEFR increased statistically significantly from 
308.7 + 107.8 I min-I to 3 19.2 f 104.0 I min-I, while in the BDP MDI group the increase was from 30 I .5 * 94.7 I min-I to 
309.3 + 86.7 I min-l.The two treatments were equally well to1erated.A total of I9 patients in each group reported adverse 
events during the treatment period, and these were generally mild-moderate in severity. In conclusion, the results of this 
study demonstrate that BDP suspension for nebulization 3000&4000 pgday-1 given via a nebulizer and BDP spray 
1500-2000 pg day- given via an MDI plus spacer are equally effective, with an acceptable safety and tolerability profile, 
when used in tieroid-dependent adult patients with moderate to severe asthma. 
0 2003 Elsevier Science Ltd 
INTRODUCTION 
Nebulization for the administration of high-dose inhaled 
corticosteroids is recommended for asthmatic patients 
who are dependent on steroid therapy and also need 
cycles of oral steroids (I).This mode of therapy facilitates 
the administration of high doses of the drugs, which may be 
delivered simultaneously to the upper and lower 
respiratory tract (2). In addition, nebulization therapy for 
corticosteroids has been reported to allow for a reduction 
in the dosage of oral steroids in severe asthmatic adults (3). 
The purpose of this study was to compare the efficacy 
and safety of a high dose of a new formulation of 
beclometasone dipropionate (BDP) suspension for 
nebulization administered via a nebulizer and high-dose 
BDP spray administered via a metered-dose inhaler 
(MDI) plus spacer (BDP MDI) in steroid-dependent 
adults with moderate to severe asthma. 
MATERIALS AND METHODS 
Male and female outpatients, aged >_ I8 to 5 70 years, 
with a clinical diagnosis of moderate to severe asthma [as 
defined by the National Heart, Lung and Blood Institute 
(4)], undergoing treatment with high-dose inhaled 
steroids at a constant daily dosage in the previous 
4 weeks, with predicted forced expiratory volume in 
I second (FEV,) of 5 60% prior to use of the inhaled 
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steroids, with stability of lung function as indicated by 
peak expiratory flow rate (PEFR), and with a positive 
response to the reversibility test (defined as an increase 
of at least 10% in FEV, measured 30 min following two 
puffs (2 x 100 pg) of inhaled salbutamol MDI) were 
eligible to participate in the study. Patients with evidence 
of asthma exacerbation or symptomatic infection of the 
airways in the previous 4 weeks, with the likelihood of 
exposure during the study to allergens or occupational 
sensitizing agents of a seasonal or episodic nature proven 
or suspected to affect the patients, with a history of 
clinically significant cardiac, renal, neurological, hepatic, or 
endocrine disease, treated with oral steroids in the 
previous 8 weeks, hypersensitive to inhaled cortico- 
steroids, involved in another trial, and with 2 +l5% 
variation in FEV, from start to end of the study run-in 
period were excluded from the randomization. 
Study design 
This was a l4-week, double-blind, double-dummy, 
randomized study undertaken in two parallel groups at 
nine centres. Following a 2-week run-in period in which 
patients continued treatment with the inhaled steroid 
that they were previously using, patients who met study 
entry criteria were assigned by randomization to one of 
the two treatment groups for a treatment period of 
I2 weeks using a daily dosage equivalent to that of the 
previously inhaled steroid: BDP suspension for 
nebulization 3000-4000 pg day-l b.i.d. (Clenil-A@, Chiesi 
Farmaceutici SpA, Italy), plus three to four puffs twice- 
daily of placebo spray, or BDP spray 1500-2000 pg day-’ 
b.i.d. (three to four puffs twice-daily) (Becloforte@,Allen 
& Hanburys, U.K.), plus placebo suspension for 
nebulization twice-daily.The suspension for nebulization 
was administered using a Pari Boy@ compressor and an 
LC Plus@ nebulizer (Pari Turbo Boy@) (Pari, Germany), 
and the spray was given via an MDI plus spacer 
(Volumatic@,Allen & Hanburys, U.K.). Inhaled (other than 
the test BDP and the permitted inhaled steroids) or oral 
corticosteroids, oral or long-acting inhaled broncho- 
dilators, antihistamines other than for rhinitis, anti- 
cholinergics, and leukotriene antagonists were excluded. 
The use of inhaled steroids during the study run-in 
period only at the same daily dosage used during the 
previous 4 weeks, inhaled salbutamol (Ventolin@, Glaxo- 
Wellcome, U.K.) given via an MDI, inhaled or oral sodium 
cromoglycate or nedocromil sodium, or theophyllines, in 
patients already receiving these and used at a constant 
daily dosage during the study period, antihistamines as 
rescue medication for rhinitis, and appropriate treatment 
for concomitant disease if it did not interfere with study 
evaluation parameters was permitted. Patients were 
assessed at various clinic visits during the study: at the 
start of the run-in period, at the start of active treat- 
ment, and at 2-week intervals post-randomization. 
Lung function measurements were conducted 
according to the Official Statement of the European 
Respiratory Society (5) in the morning at approximately 
the same hour of the day. Spirometric lung function 
parameters were measured at each clinic visit. Morning 
and evening PEFRs were measured daily by patients using 
the Mini-Wright@ peak flow meter (Markos, Italy/ 
Clement Clarke International, U.K.) and the highest of 
three measurements recorded on a diary card. Clinical 
symptoms scores, rated on a four-point scale (from O=no 
symptoms to 3=severe symptoms), and salbutamol 
consumption, were also assessed daily by patients and 
recorded on a diary card. Patient opinion of efficacy, and 
investigator opinion of tolerability based on adverse drug 
reactions, were rated on a four-point scale ranging from 
‘poor’ to ‘excellent’ and recorded at study end. Morning 
serum cortisol levels were measured at the start and end 
of randomization, and vital signs at each clinic visit. The 
institutional review board for each treatment centre 
approved the protocol, and written informed consent 
was obtained from the patients. 
Assessments 
The primary efficacy endpoint was morning PEFR. 
Secondary efficacy variables were evening PEFR, FEV,, 
forced vital capacity (FVC), daily salbutamol 
consumption, clinical symptoms scores, and patient 
opinion of efficacy.The primary safety parameter was the 
morning serum cortisol level. Secondary safety variables 
included adverse events and adverse drug reactions, vital 
signs (heart rate and blood pressure), and investigator 
opinion of tolerability. 
Statistical analysis 
Sample size calculation (6) was based on the criteria of 
equivalent efficacy between the two treatments. 
Considering as the primary efficacy variable the final 
mean value of morning PEFR,the following was taken into 
account: the baseline-adjusted final mean value obtained 
in the BDP MDI group was estimated to equal 
460 I min-I; the equivalence of efficacy between groups 
was defined as a difference between mean values not 
more than 10% of the BDP MDI mean; the standard 
deviation of the difference between mean values was 
estimated as equal to 70 I min-’ ; the expected difference 
between the mean value in the two groups was estimated 
as equal to 0; the power of the trial was defined as equal 
to 80% and the level of significance equal to 5%. 
Statistical significance in the study was declared if 
PsO.05. Baseline values were compared using an ANOVA 
(analysis of variance) model (including a term for 
treatment effect) for continuous variables, and by the 
Wilcoxon two-sample test or Chi-square test for 
categorical variables. 
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Within-treatment comparisons for morning PEFR were 
analysed by calculating the 95% confidence interval for 
the mean change from baseline, and between-treatment 
comparisons by using the analysis of covariance 
(ANCOVA) model for values at each study visit. This 
model included terms for investigator and treatment 
effects and baseline value as a covariate. A preliminary 
test for the investigator-by-treatment interaction was 
undertaken at 0. IO significance level. Therapeutic 
equivalence between the two treatments was evaluated 
by calculating the 95% confidence intervals for the 
difference between the least square means (LSM), from 
ANCOVA, in the two groups. The two test treatments 
were defined to be equivalent if the confidence limits for 
the difference fell within f 10% of the least square- 
adjusted mean of the BDP MDI group. Furthermore, BDP 
nebulization was defined as non-inferior to BDP MDI if 
the lower limit of the unilateral confidence interval for 
the difference in morning PEFR did not exceed -IO%. 
Secondary efficacy parameters were analysed by 
calculating the 95% confidence interval for the mean 
change from baseline at each visit (for variables 
measured at clinic visits) or at each 2-week period (for 
values recorded by patients), and within- and between- 
treatment comparisons were undertaken using 
ANCOVA. Patient opinion of efficacy was compared 
using the Chi-square test. 
Morning cortisol serum levels and cardiovascular 
parameters were analysed by calculating the 95% 
confidence intervals for the changes from baseline. 
Between-treatment comparisons for cortisol levels were 
made using the unpaired t test, for the incidence of 
adverse events, and adverse drug reactions, using the 
Chi-square test or the two-tailed Fisher’s exact test, and 
for investigator opinion of tolerability using the Chi- 
square test. 
All randomized patients who received at least one 
dose of the study medications and with at least one visit 
after baseline were included in the intent-to-treat (ITT) 
analysis. Missing data were replaced with the LOCF (last 
observation carried forward) method. All patients 
included in the ITT analysis who also met study entry 
criteria and did not have any major protocol violations 
were included in the per protocol (PP) analysis. The 
primary efficacy variable was analysed both for the ITT 
and PP populations, while all other efficacy parameters 
were analysed on an ITT basis only. 
RESULTS 
Patient population 
Of the I35 patients screened for the study, I24 patients 
were randomized: 63 to the BDP nebulization group, and 
6 I to the BDP MDI group. Nine patients (four in the BDP 
nebulization group and five in the BDP MDI group) were 
withdrawn during the active treatment period due to 
various reasons, and I2 patients (six in each treatment 
group) were excluded from the PP population due to 
major protocol violations. The ITT population was 
therefore made up of I24 patients (63 treated with BDP 
nebulization and 6 I treated with BDP MDI), and the PP 
population of I I2 patients (57 treated with BDP 
nebulization and 55 treated with BDP MDI).Assessment 
of safety of the two treatments was based on the ITT 
population. Patient demography and values for lung 
function parameters at baseline were comparable for the 
two groups in the randomized population (Table I). 
Evaluation of efficacy: Morning PEFR 
Comparable and statistically significant improvements in 
morning PEFR were reported over baseline in both the 
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FIGURE I. Mean values for morning peak expiratory flow rate in the (a) intent-to-treat and (b) per protocol populations of steroid- 
dependent adults with moderate to severe asthma at baseline and during I2 weeks of treatment with beclometasone dipropionate 
given by nebulization or metered-dose-inhalation. 
BDP nebulization and BDP MDI groups in the ITT 
population at the end of the 12-week treatment period. 
In the BDP nebulization group, mean values increased 
from 308.7 I min-1 to 3 19.2 I min-I, while in the BDP MDI 
group the increase was from 30 I .5 I min-I to 
309.3 I min-I (Figure I). Similar results were also seen in 
the PP analysis, with mean values increasing from 
305. I I mini at baseline to 3 15.4 I min-1 at treatment end 
in the BDP nebulization group, and from 299.6 I min-I to 
307.6 I min-I in the BDP MDI group (Figure I). 
Furthermore, the lower limit of the unilateral confidence 
interval was -7.4 and -8.4 in the ITT and PP populations, 
respectively, and did not exceed -IO% (-3 I .4 and -3 I. I, 
respectively) of the adjusted mean of the BDP MDI group, 
thus demonstrating that BDP nebulization was not 
inferior to BDP MDI. In addition, the 95% bilateral 
confidence intervals for the difference between the LSM 
in the ANCOVA model were -9.6; 17.3 for the ITT 
population, and -I I .O; 18.3 for the PP population, and fell 
within f IO% of the adjusted mean of the BDP MDI group 
(+3 I .4 I min-I and *3 I. I I min-I, respectively), to confirm 
that the two treatments were equivalent. 
Evaluation of efficacy: Other measures 
of pulmonary function 
Statistically significant improvements were seen over 
baseline in both groups in the ITT population at treatment 
end in evening PEFR, FEV,, and FVC, with no significant 
differences found between the two treatment arms for 
any of these parameters (Figure 2). Mean values for the 
BDP nebulization and BDP MDI groups, respectively, 
increased from 320. I I min-1 to 333.8 I min-’ and from 
3 13.5 I min-I to 326.6 I min-1 for evening PEFR, from I .8 
to 2.2 litres and from I .9 to 2.2 litres for FEV,, and from 
2.6 to 3-O litres and from 2.8 to 3.0 litres for FVC. 
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FIGURE 2. Mean values for various lung function parameters in 
the intent-to-treat population of steroid-dependent adults with 
moderate to severe asthma before and after 12 weelcs of 
treatment with beclometasone dipropionate given by 
nebulization or metered-dose-Inhalation. 
Evaluation of efficacy: Signs and 
symptoms and rescue medication 
At study end, similar and statistically significant 
reductions in the sum of clinical symptoms scores were 
observed over baseline in the two treatment groups 
when analysed on an ITT basis. Scores fell from 4.3 to 3.2 
in BDP nebulization-treated patients, and from 4.6 to 3.4 
in the BDP MDI group. 
Reductions in the daily consumption of salbutamol 
were also noted in both treatment arms at the end of 
the study when compared with baseline, these being 
statistically significant in the BDP nebulization group at 
the end of the test treatment period, and in the BDP 
MDI group at 2 weeks post-treatment.At study end, the 
difference between the two groups was non-significant, 
with the mean daily number of puffs falling from 
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3.8 puffs day’ at baseline to 3.3 puffs day’ in the BDP 
nebulization group, and from 3.7 puffs day-r to 
3.4 puffs day-’ in the BDP MDI group. 
Evaluation of efficacy: Patient opinion 
The majority of patients in both treatment groups in the 
ITT population considered efficacy as ‘excellent’ or ‘good’ 
(83% and 82.2% of patients in the BDP nebulization and 
BDP MDI groups, respectively), with no significant 
difference noted between the two treatment arms. 
Evaluation of safety 
Safety data showed that both treatments were well 
tolerated. During the treatment period, I9 patients in 
each group (30.2% and 3 I. I % of BDP nebulization- 
treated and BDP MDI-treated patients, respectively) 
reported adverse events (NS between treatments) 
(Table 2). The respective number of adverse events was 
29 (46%) and 3 I (50.8%) and these tended to be mild to 
moderate in severity and were generally associated with 
the respiratory system. In total, I I patients reported 
adverse drug reactions: six (9.5%) in the BDP nebulization 
group, and five (8.2%) in the BDP MDI group, with I3 
(20.6%) and 7 (I I .5%) adverse drug reactions seen in the 
respective groups. Adverse drug reactions generally 
consisted of local irritation or infection/inflammation. 
Only two patients (one in each group) were withdrawn 
from the study due to adverse events. 
The two treatments had a similar effect with respect 
to morning serum cortisol levels at treatment end, and 
no clinically or statistically relevant changes were found 
for vital signs within or between groups during the 
treatment period. Furthermore, investigator opinion of 
tolerability was ‘excellent’ or ‘good’ in 96.6% and 94.6% 
of patients in the BDP nebulization and BDP MDI groups, 
respectively (NS between treatments). 
DISCUSSION 
This study was designed to evaluate the efficacy and 
safety of a high dose of a new formulation of BDP 
suspension for nebulization given via a nebulizer and 
high-dose BDP spray given using an MDI plus spacer as a 
I2-week treatment for moderate-severe asthma in adult 
patients dependent on high-dose inhaled steroids. 
Although no previous studies have compared BDP 
delivered via nebulizer and MDI, many studies in adults 
involving bronchodilators have compared these two 
delivery devices. A recent review by Brocklebank et al. 
described a combined analysis of 21 studies in adult 
stable asthma (7).They found equivalence for the main 
pulmonary outcomes and no evidence of difference in 
other outcomes. In summary, the authors concluded that 
the dosage equivalence ratio of MDI to nebulizer is 
l:2-l:6. 
The results of this study demonstrated that nebulized 
and MDI forms of BDP significantly, and to a similar 
degree, improved pulmonary function and asthma 
symptoms, and reduced the need for rescue medication. 
The majority of patients in both groups also considered 
efficacy to be ‘good’ or ‘excellent’. Furthermore, 
statistical analysis of the results for the primary efficacy 
variable of morning PEFR confirmed that BDP 
nebulization was not inferior to BDP MDI and that the 
two treatments were equivalent. When considering that 
the daily dosage of the two treatments was equivalent to 
that of the previous treatment with inhaled cortico- 
steroids, it is noteworthy that there was still scope for 
improvement for the efficacy parameters evaluated, as 
demonstrated by the differences over baseline in both 
groups. This can be explained by the good compliance 
(the administration of at least 75% of the scheduled 
doses), of around 90%, with the two treatments. It is also 
important to note that compliance was evaluated using a 
very restrictive method that required the use of the 
minimum necessary doses of the active drugs and the 
alternative placebo. In addition, the safety profile was 
shown to be comparable for the two treatments with 
respect to the incidence of adverse events, potential 
adrenal suppression (as indicated by morning serum 
cortisol levels), and vital signs. 
In conclusion, this study demonstrates that BDP 
suspension for nebulization 30004000 ug day’ given via 
a nebulizer and BDP spray 1500-2000 ug day’ given via 
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an MDI plus spacer are effective and therapeutically 
equivalent, with a good safety and tolerability 
when used as a treatment for moderate to 
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